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Abstract  
 
This project was focused on studies of the location and function of selected 
purinergic receptors in the rat urinary bladder. Its special concerns are on adenosine 
P1A1 purinoceptors and on their expression in healthy and inflamed urinary bladders 
of the rat.  
It was found that both P2X1 and P1A1 receptors are expressed in urinary 
bladder. The quantity of P1A1 receptors is decreased in the inflamed bladder. 
Functional studies based on an agonist stimulation (adenosine) showed importance of 
P1A1 receptors for relaxation of the tissue. During the cystitis this effect was 
reduced. Electric field stimulation (EFS) pointed out the difference between the 
response to a stimulus affecting just postsynaptic receptors (adenosine stimulation) 
and responses to nerve stimulation including both post- and presynaptic effects. 
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Abstrakt 
 
 
Tato práce je zaměřena na určení výskytu a funkce vybraných purinergních 
receptorů v močovém měchýři potkana. Zabývá se zejména adenosinovými P1A1 
purinoceptory a jejich expresí ve zdravém a zaníceném močovém měchýři. 
Studie ukázala, že jak P2X1, tak P1A1 purinoceptory jsou přítomny v močovém 
měchýři potkana. U P1A1 receptorů je jejich exprese během zánětlivého onemocnění 
signifikantně snížena. Funkční studie založené na stimulaci agonistou (adenosinem) 
ukázaly na význam P1A1 receptorů během relaxace studované tkáně. Během zánětu 
je tento vliv částečně potlačen. Stimulace vzorku elektrickým proudem  (Electric 
field stimulation) pak poukázala na rozdíl ve funkční odpovědi receptorů 
stimulovaných jen postsynapticky (adenosinem) a stimulovaných post- a zároveň 
presynapticky.  
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“Overactive bladder (OAB) is a common, disabling condition associated 
with considerable negative impact on quality of life, quality of sleep, and mental 
health. The age-specific prevalence of OAB is similar among men and women. 
Urge incontinence affects only a portion of the OAB population: 33% of 
patients have OAB with urge incontinence ("OAB wet"), while 66% have OAB 
without urge incontinence ("OAB dry"). The symptoms of OAB can affect 
social, psychological, occupational, domestic, physical, and sexual aspects of life. 
OAB can also lead to depression and low self-esteem.” (Tubaro, 2004) 
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1 Introduction 
  
Impulses in parasympathetic nervous system elicit the contractions of detrusor 
muscle of the urinary bladder which lead to voiding. However, it has been proved 
that the parasympathetic stimulation of the urinary bladder through the muscarinic 
receptors is not the only way of affecting it. There are also responses of the tissue 
that are resistant to atropine (Langley & Anderson, 1895). Consequently there must 
be other transmitters than sympathetic noradrenaline and parasympathetic 
acetylcholine affecting the urinary bladder. As one of these transmitters ATP was 
proposed (Burnstock et al., 1970). It generates a contraction by acting on P2X 
receptors and this contraction is followed by a relaxation which is believed to be 
generated by adenosine, the ATP breakdown product, acting on the P1 (adenosine) 
receptors. The adenosine effect via P1 receptors is thus inhibition of contractile 
mechanisms (Giglio et al., 2001). 
During the inflammatory process in the urinary bladder the expressions of 
muscarinic and P2 receptors are increased. This higher appearance can cause a 
disordered state of urinary bladder, which is called an overactive urinary bladder. 
The imbalance in the vegetative innervation leads to several bladder dysfunctions, 
which the patient apprehends as uncomfortable, such as frequency of voidings 
caused by insufficient contraction and over-dilatation of the bladder or very strong 
and sharp pain, both the result from increased expression of the receptors. It is 
suggested that the P1 receptors are involved in this pathological process also. 
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2 Review of literature 
 
2.1 Urinary bladder 
 
2.1.1   Clinical aspects of the urinary bladder 
 
The lower urinary tract is composed of the bladder and the urethra—the two 
functional units for storage (the bladder body, or reservoir) and elimination (the 
bladder neck and urethra, or outlet) of urine (Chancellor & Yoshimura, 2004). 
The urinary bladder is a concave, muscular organ, which is located in pelvic 
cavity under the peritoneum and behind the symphysis pubic. The urinary bladder 
consists of three parts- the fundus (lower part), the corpus (middle part) and the apex 
(top). Its septum is composed of mucous membrane, submucousa and muscle. The 
ureters enter and the urethra drains the bladder in the fundus. 
The function of the urinary bladder is to store the urine incoming from the 
kidneys and to expel the urine through the urethra out of the body. It works almost as 
a ball. Incoming urine increase the pressure in the bladder, the muscle fibres conform 
to a volume of urine and the bladder relaxes until the wall is stretched. 
First urge to micturition in human body is experienced when the bladder is 
filled to about 150 ml, and a distinct urge when it is about 300-400 ml. Rejection of 
micturition is possible till the bladder is filled up to 700-750 ml. 
 
2.1.2   Anatomy of the urinary bladder 
 
The bladder is extraperitoneal and roughly pyramidal (Fig. 2.1). From the 
superior side it is covered by the pelvic peritoneum with parts of small intestine and 
the sigmoid loop lying against it. The bladder can be divided into two main 
components:
 
the bladder body, which is located above the ureteral orifices,
 
and the 
base, consisting of the trigone, urethrovesical junction,
 
deep detrusor, and the 
anterior bladder wall. Anteriorly, the bladder lies behind the pubis with its apex 
attached by a fibrous strand, the median umbilical ligament, to the umbilicus. This 
represents the remains of the fetal urachus. Posteriorly in the male, the base of the 
 12 
bladder relates to the rectum, the vasa deferentia and the seminal vesicles; in the 
female, to the vagina and the supravaginal cervix. It receives the ureters at its upper 
lateral angles. Laterally, the inferolateral surfaces relate to the levator ani and 
obturator internus muscles on each side. The bladder neck fuses with the male 
prostate; in the female it rests directly on the pelvic fascia.  
As the bladder distends, during the filling with urine, it becomes spherical and 
projects into the lower abdomen, pushing the peritoneum upwards from the anterior 
abdominal wall. This may allow a safe extraperitoneal puncture of the distended 
bladder to be performed.  
In the infant, the pelvis is comparatively small and therefore the bladder neck is 
in level with the upper part of the symphysis and the bladder itself, although still 
extraperitoneal, is in contact with the anterior abdominal wall.  
The interior of the bladder is readily visualized through the cystoscope. The 
ureteric orifices are seen as a slit on either side. Between them, a raised fold of 
mucosa, the inter-ureteric ridge, is constantly visible, produced by an underlying bar 
of muscle. Between the ureteric orifices and the urethral orifice is the smooth 
triangular area of the trigone. The smooth muscle of the bladder wall is formed by a 
criss-cross of fibres. When these undergo hypertrophy as a result of chronic urethral 
obstruction, they produce the characteristic trabeculated appearance at cystoscopy. 
Blood is supplied from the superior and inferior vesical branches of the internal iliac 
artery. The vesical veins form a plexus which drains into the internal iliac vein. 
Lymphatics drain along the vesical blood vessels to the iliac and then the para-aortic 
nodes.  
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Fig. 2.1: Anatomy of human urinary bladder  
(adapted from: http://www.daviddarling.info/images/urinary_bladder.jpg) 
 
In males, the urethra is 18- 20 cm long and consists of three parts: i., prostatic 
– 3-4 cm long and it goes through the prostate; ii.,membranous – 2 cm long, the 
narrowest part of the urethra, traverses the external urethral sphincter; iii., spongy – 
15 cm long and traverses the corpus spongiosum of the penis (Ellis, 2005). In 
females, the urethra is approximately only 4 cm long, extending from the anterior 
wall to the external meatus.   
 
2.1.3   Histology of the bladder 
  
The tissue layers of the whole of the lower urinary tract, thus including the 
renal pelvic and the urethers, are the same. The layers are mucosa, muscularis and 
serosa/ adventina (Fig. 2.2, Fig. 2.3). 
A) Histology of mucosa (urothelium): The mucosa is the innermost portion of 
the urinary bladder. It is composed of transitional epithelium and connective tissue. 
The transitional epithelium, also called the urothelium, is a stratified epithelium 
lining the distensible walls of the urinary tract. The name "transitional" derives from 
this tissue's ability to change its shape from cuboidal to squamous when stretched. It 
is observed that the transitional epithelium consists of domed shaped cells on the 
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apical surface. The epithelial layer contains no blood vessels or lymphatic vessels. 
The basement membrane is composed of a single layer of cells and separates the 
epithelium and the connective tissue. The epithelium located on the connective tissue 
is called the lamina propria. The lamina propria is composed of areolar connective 
tissue and it contains blood vessels, nerves and in some regions even glands. 
B) Histology of muscularis (smooth muscle- detrusor): The bladder muscular 
wall is formed by smooth muscle
 
cells, which comprise the detrusor muscle. The 
detrusor is structurally
 
and functionally different from, e.g., trigonal and urethral
 
smooth muscle. Three layers of smooth muscle have
 
been described. The cells of the 
outer and inner layers tend
 
to be oriented longitudinally, and those of the middle 
layer
 
circularly. In the human detrusor, bundles of muscle cells of
 
various sizes are 
surrounded by connective tissue rich in collagen. Cells
 
with long dendritic processes 
can be found in parallel to the smooth
 
muscle fibers. These cells contain vimentin, an 
intermediate
 
filament protein expressed by cells of mesenchymal origin, and of 
nonmuscle myosin (Andersson & Arner, 2004).                        
C) Histology of serosa: There is a serosal covering on the upper region of the 
bladder. On a histology slide, it is apparent that the serosa is composed of a simple 
squamous epithelium overlying a small bit of connective tissue. The serosa is part of 
the peritoneum. In all other regions of the bladder, the outer layer of the bladder is 
formed by the adventitia. The adventitia is composed of connective tissue. Beyond 
the serosa/adventitia covering of the bladder perivesical fat occurs, which surrounds 
the bladder. 
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Fig. 2.2: Histology of distended urinary bladder  
(adapted from: http://www.bu.edu/histology/p/16604loa.htm) 
   
A muscularis mucosae is present in all regions of the human urinary bladder. 
This tissue is discontinuous and it consists of irregularly-arranged muscle bundles 
composed of relatively small smooth muscle cells. These cells are different 
morphologically and histochemically from the detrusor muscle cells from which they 
originate. They are rich in non-specific cholinesterase and glycogen. The muscularis 
mucosae also contain acetylcholinesterase-positive nerve fibres. The constituent 
smooth muscle cells contain an extensive sarcoplasmatic reticulum and large 
peripheral clusters of dense glycogen granules. The myofilaments are concentrated in 
the center of the cells. Between adjoining cells, many intercellular junctions occur 
where presumptive cholinergic nerve terminals, which lie close to the muscle cell 
surface and contain small agranular and large granulated vesicles (Dixon & Gosling, 
1983). 
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Fig. 2.3: Histology of contracted urinary bladder 
 (adapted from http://www.bu.edu/histology/p/16501lca.htm) 
 
 
2.2 Incontinence 
 
Incontinence is one of the most common chronic diseases in women and it is 
found in 17-60% of the whole population (Starczewski et al., 2008). Continence and 
micturition involve a balance between urethral closure and detrusor muscle activity. 
Urethral pressure is normally higher than the bladder pressure, which maintains 
continence. Both the proximal urethra and the bladder are located in the pelvis. 
Intraabdominal pressure increases (from coughing and sneezing) are equally 
transmited to both the urethra and the bladder. However the pressure difference may 
be changed towards a larger bladder pressure, which thus may result in incontinence. 
Normal voiding is the result of changes in both of these pressure factors: urethral 
pressure falls and bladder pressure rises. Incontinence is a significant health issue in 
that it has physical, social and economic implications for women and men of all ages 
as well as children, families and the community. 
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Types of incontinence: 
1. Stress urinary incontinence (SUI): involves involuntary leakage of urine in 
response to abdominal pressure caused by activities such as sneezing and coughing 
(Chancellor & Yoshimura, 2004). Also physical changes resulting from pregnancy, 
childbirth and menopause often cause stress incontinence. In men this type of 
incontinence often follow the prostatectomy. It is the most common form of 
incontinence in women and it is often treatable. 
 
2. Urge incontinence: is an involuntary loss of urine occurring for no apparent 
reason often combined with a sudden feeling of the need to urinate. The most 
common cause of urge incontinence is involuntary and inappropriate detrusor muscle 
contraction.  
Idiopathic detrusor overactivity: local or surrounding infection, inflammation 
or irritation of the bladder. 
Neurogenic detrusor overactivity: defective CNS inhibitory response. The 
bladder is described to be unstable, plastic or overactive. Urge incontinence may also 
be called reflex incontinence if it is the result from overactive nerves controlling the 
bladder. Patients with this type of incontinence may suffer during sleep, after 
drinking small amounts of water or even when hearing it running (for example 
during washing dishes or if somebody else is taking a shower). The reasons for the 
involuntary actions of bladder muscles can be damages of the nerves to the bladder, 
of the central nervous system (spinal cord and brain) or the muscles themselves. 
Bladder nerves or muscles can be harmed by diseases such as Parkinson´s, 
Alzheimer´s, Sclerosis Multiplex, stroke or injury including the ones which can 
occur after surgery. 
 
3. Functional incontinence: it occurs when a person does not recognize the 
need to go to the toilet in time. The urine loss may be large. The reasons of 
functional incontinence include confusion, dementia, poor eyesight, poor mobility, 
poor dexterity or unwillingness to toilet because of depression, anxiety or anger. 
There are also environmental factors, which may contribute to this type of 
incontinence, such as poor lighting, low chairs that are difficult to get out of, and 
toilets that are difficult to access (Australian Government, 2008). 
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4. Overflow incontinence: is the type of incontinence where the bladder 
becomes too full because it cannot be fully emptied (Starczewski et al., 2008). It can 
occur either because the outflow of the urine is blocked or because the bladder 
becomes underactive. The blockage can be caused by an enlarged prostatic gland, 
constipation or narrowing of the urethra. Symptoms may include frequency, urgency, 
nocturia, in-completed bladder emptying or frequent urinary tract infections. An 
underactive bladder may be the result from spinal injuries, a complications of 
diabetes, sclerosis multiplex or tumors. 
 
5. Bedwetting: is an episodic urinary incontinence while asleep. It is normal in 
young children. But it can also be connected to sleep-disordered breathing such 
obstructive sleep apnea (Umlauf & Chasens, 2003). 
 
6. Other types of incontinence: Are mainly considered as a ―mixed 
incontinence‖. Quite often a combination of stress and urge incontinence occurs in 
women but may also occur in elderly patients irrespective of sex. 
 
 
2.3 Overactive bladder (OAB) and other LUTS 
 
A symptom complex with urgency, with or without incontinence, and usually 
accompanied by urinary frequency and nocturia has been designated ―overactive 
bladder‖ (OAB) (Michel & Barendrecht, 2008). OAB is a symptom, which is very 
common, especially for the elderly. The prevalence increases with the increasing age 
(it occures in 17% older than 18 years, at the age of 75 years: 31% women, 42% 
men) (Mašata, 2007). 
The definition of overactive bladder according to International Continence 
Society (ICS) is a complex of symptoms of a dysfunction of the low urinary tract. 
The typical symptom of OAB is urgency, which can be connected with incontinence. 
Other symptoms are frequency and nocturia. The OAB has a huge negative impact 
on quality of life of the patients.  
The International Continence Society (ICS) has been trying since 1976 to 
uniform the terminology regarding function and dysfunction of the lower urinary 
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tract. Last Report from the Standardization Sub-committee was published in 2002 
and this report can be considered as a golden standard. This thesis follows by this 
Report standardized lower urinary tract symptoms (LUTS) and other symptoms 
which are related to this issue of classification and description of the symptoms in 
very detail. 
LUTS – symptoms as subjective indicator of disease or as a change of state 
noticed by patient, career or partner. LUTS is devided into three main groups: 
1. storage of the symptoms 
2. voiding symptoms – symptoms during voiding 
3. post micturition symptoms, 
 
There are four additional categories of classification: 
i. symptoms associated with the sexual intercourse 
ii. symptoms associated with pelvic organ prolapse 
iii. with genital and lower urinary tract pain 
iv. symptom syndromes.  
The LUTS are mainly defined according the individual (mainly patients) 
perspective (Homma, 2008).   
 
Urgency – The report defines urgency as a complain to sudden invincible 
feeling for micturition which is difficult to overcome. Urgency is then ―strong desire 
to void with an abrupt onset‖. Healthy people would have similar feeling to void 
when they would not be able to go to the bathroom for a very long time.  
Frequency – The report defines ―increased daytime frequency‖ as a complain 
of patient who thinks he voids very often during the day. This is also called 
pollakisuria. Nocturia (nycturia) is trouble, when the patient has to get up once or 
more during the night to go to the bathroom to void. In this context the night is 
defined as a space of time between when the patient goes to bed until he wakes up in 
the morning. 
―The increased daytime frequency‖ is the complain of the patient and that is 
why a voiding five times a day is considered as a symptom when the patient feels 
that way, while the voiding fifteen times a day is not considered as a symptom when 
the patient does not mind it is too often. Contrary to this nocturia is a symptom even 
when there is just one occasion per night when the patient goes to the toilet.  
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The definition can be then explained in other words that voiding before going 
to the bed or voiding early in the morning which hinder the patient to fall asleep 
again are not considered as the nocturia. Also the waking up during the night by 
other reason than the feeling for voiding (for example noise) but followed by a toilet 
visit, is not considered as nocturia. 
These voidings which occur during the night, but not defined as a nocturia, are 
called ―the nighttime frequency‖. Consequently nocturia does not ―cover‖ either 
voiding between going to the bed and falling asleep nor waking up and getting out of 
the bed (Homma, 2008). 
The principal symptom of OAB is the urgency. Contrary to the physiological 
need to mictate, the urgency comes suddenly and forces the patient to an immediate 
emptying. The time between the first feelings for micturition to the eventual outflow 
of the urine is usually getting shorter, the frequency is rising and the volume of each 
voiding is lowering.  
 
 
2.4 Neurophysiology of micturition   
 
Both central (supraspinal and spinal) and peripheral (pelvic parasympathetic, 
lumbar sympathetic and somatic pudendal nerve) pathways of the nervous system are 
activated regulating the lower urinary tract function. The center for micturition (pons 
and periaqueductal grey matter of midbrain) is organizing the micturition operational 
reflex functions between the higher centers of the brain and the urinary tract 
(Kennelly & Devoe, 2008). The basal ganglia, cerebellum, cerebral cortex, thalamus, 
and hypothalamus have influence on the micturition center. 
The peripheral innervation for the bladder involves the sympathetic, 
parasympathetic, and also somatic nerves. The bladder receives the sympathetic 
innervation via the hypogastric nerve and parasympathetic innervation mainly by the 
pelvic nerve. The detrusor muscle relaxation and bladder neck contraction is 
mediated by activation of sympathetic verves from thoracolumbal spinal cord T12-
L2 segments. This results in gradual distention of the bladder without any 
pronounced increase in bladder pressure. When threshold volume is reached, 
afferents are activated and via the central nervous system sympathetic impulses are 
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inhibited and parasympathetic activated. By activation of the parasympathetic nerves 
from sacral cord S2-S4 segments, detrusor is stimulated to contract and this promotes 
voiding. Axons of Onuf´s nucleus (an area in the sacral spinal cord involved in the 
maintenance of urinary and defecatory continence, as well as a muscular contraction, 
e.g., during an orgasm) contains motor neurons, and is also the origin of the pudendal 
nerve in the sacral cord segment (S2-S4). The external urethral sphincter is 
innervated by the pudendal nerve.   
The voluntary voiding is normally achieved by voluntary relaxation of the 
external urethral sphincter, allowing release of urine (Blaivas, 1982). 
During the
 
filling of the urinary bladder, the smooth muscle cells have
 
to relax 
and to elongate the wall over a very
 
large length interval. During micturition, the 
force generation
 
and shortening must be initiated comparatively fast
 
and to occur 
over a large length range. These activities thus require
 
both regulation of contraction 
and regulation of relaxation.
 
To respond to the nervous and hormonal control 
systems, each
 
part of the urinary tract muscles has to have specific receptors
 
for the 
transmitters/modulators, released from nerves, endocrine glands or generated
 
locally, 
and a distinct receptor coupling to the associated cellular pathways for initiating
 
contraction and relaxation (Andersson & Arner, 2004). 
 
2.5 Neural control 
2.5.1 Receptors 
 
Neurotransmitter needs a reaction partner to bind to so it could induce an 
effect. These transmitters binding partners are the receptor proteins, also called 
receptors. 
Receptors have got two main properties: 
-they have a specific binding area, which is able to connect to just a specific 
transmitter 
-after the transmitter is bound, the receptor protein changes its conformation, 
resulting in a functional state. 
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2.5.2 Types of the receptors 
 
Ligand gated ion channel  
One example of ligand gated channels (Fig. 2.4) is the nicotine-acetylcholine 
receptors situated in the nerve-muscle plate belong to this group. The receptor is 
composed of four glycoprotein subunits () of molecular mass 40-60 kDa. It 
is inserted in the membrane and there is a trans-membrane channel going through the 
center of these five member group of molecules. Every subunit is composed of a 
protein fibre   constituting an- helix. Two of five subunits are identical and each of 
them carries one binding spot for acetylcholine. The general name for the receptor 
binding substance is ―ligand‖. 
 
 
 
Fig. 2.4: Ligand gated ion channel (adapted from: 
 http://www-hsc.usc.edu/~bolger/ced/autonomic/images/N1-Nicotinic.jpg) 
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When released from the neuronal terminal of the motoric nerve, two of the 
acetylcholine molecules occupy the binding spots of the receptor and open the 
channel. The influx of sodium is functionally most important. It causes a 
depolarization of nerve-muscle plate and the depolarization is then spread.      
The acetylcholine molecule does not bind to the receptor for very long. It is in 
short loosened and it meets an acetylcholinesterase and is by the enzyme dissociated. 
This whole machinery takes just few milliseconds. This is how a fast skeletal muscle 
movement is regulated.   
 
 
 
G proteins coupled receptors 
  
Many receptors of the human body belong to the G protein coupled group of 
receptors (Fig.2.5). The examples of receptors belonging to this group are numerous 
and include muscarinic receptors, adrenoceptors and histamine receptors. 
The typical receptor protein of this group is a peptidic chain of ca 500 amino-
acids having a molecule mass of approximately 60 kDa. It is an - helix which 
transmigrate through the membrane seven times. It does seem as it is organized in a 
circle and somehow it creates a kind of cavern – a perfect place for transmitter 
binding.  
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Fig. 2.5: G protein coupled receptor 
 (adapted from:  http://structbio.vanderbilt.edu/sanders/Gpcr.jpg) 
 
Signal transduction (Fig. 2.6) is provided by a guanyl-nucleotide – the G 
protein. This protein is located at the inner side of the membrane and it is able to 
move laterally. The G protein is composed of three subunits  (5kDa),  (35kDa) 
and  (7kDa). During a state of resting, a molecule of guanosindiphosphate (GDP) is 
bound to the  subunit.  
When the transmitter connects to the receptor, GDP is released from the  
subunit and the  subunit is then free to bind to the guanosintripohsphate (GTP) 
molecule and move away of the other units of the G protein. By that it can reach the 
―effector proteins‖ and change their functional state.  
Another important effector protein is an adenylatecyclas. It catalyses a 
production of cyclic adenosinemonophosphate (cAMP), which is an intracellular 
messenger.   
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Fig. 2.6: Signal transduction  
(adapted from: http://www.scielo.br/img/fbpe/abc/v72n2/a09fig01.gif)                                   
  
  
Besides the receptor groups mentioned above, other receptor types occur. 
These groups generally regulate long-term effects and exert their effect after a longer 
latency. Examples of effects that can exerted are enzyme activity and DNA 
transcription (Lüllmann et al., 2003). 
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2.6 Urinary bladder and its receptors 
 
2.6.1 Cholinergic Mechanisms 
 
2.6.1.1 Muscarinic receptors  
 
In most animal species, bladder contraction is mediated by both
 
cholinergic and 
nonadrenergic, noncholinergic (NANC) mechanisms. However, the cholinergic 
response seems to be the functionally most important in more or less all species. It 
has been showed that acetylcholine produces a slight depolarization and causes a 
contraction of the muscle. These contractions are extended by cholinesterase 
inhibitors and abolished by atropine. Muscarinic receptors (M1 – M5) mediate 
metabotropic activity of acetylcholine in nerve systems. An overwhelming amount of 
data shows that they also interpose autocrine function of the molecule (Eglen, 2006).   
The detrusor smooth muscle contains muscarinic receptors mainly of the M2 
and M3 subtypes but it has been observed that mRNAs for all muscarinic receptor 
subtypes occur in the tissue. Muscarinic receptors are G protein coupled as 
mentioned previously and regarding the contraction, this is their functional 
connection. But the signal transduction varies according to other effects in the 
bladder. 
In the human bladder the muscarinic receptors are believed
 
to cause a direct 
smooth muscle contraction through phosphoinositide
 
hydrolysis (Andersson et al., 
1991). Bladder smooth muscle
 
might have a difference in the localization of 
muscarinic receptors,
 
in that junctional receptors may be M2 receptors, and while
 
extrajunctional receptors are M3 receptors (Hashitani et al., 2000). Nevertheless, 
there is general agreement that M3 receptors are mainly responsible
 
for the normal 
micturition contraction (Andersson & Arner, 2004). 
 The contraction of the detrusor muscle of the bladder is thus caused by 
activation of M3 muscarinic receptors. But there are actually more of the M2 
receptors in the urinary bladder but the physiological function is not properly known 
yet. One of the suggestions is that it oppose the relaxant stimuli of the -
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adrenoceptors which is supposed to be important for the physiological way of the 
micturition. But some functional studies also showed M2 receptors have direct and 
small contractile effects on the urinary bladder. 
 
2.6.1.2 Therapeutic use of drugs acting on M receptors 
 
The problem with drugs acting on muscarinic receptors has been the frequent 
occurrence of adverse effects, since muscarinic receptors regulate a number of 
mechanisms in almost every part of the body. And even though cholinergically 
acting drugs with different selectivity for the muscarinic subtypes exist, the 
selectivity window is too small to be clinically useful. However, different approaches 
have been tried in order to overcome the problem. According to cognitive disorders, 
selective M1 agonists or combination of M1 agonists and M2 antagonists have been 
suggested to be one of the possible ways how to cure the disorders, and M3 
antagonists or M2/M3 antagonists are accepted for treatment of contractile diseases 
including overactive bladder and chronic obstructive pulmonary disease. Practical 
data shows selective antagonists for M4 receptors will act as a new anti-nociceptive 
agens. Therapeutic effective antagonists and agonists on M5 receptors are currently 
missing (Eglen, 2006). 
  
 
2.6.2 Adrenergic Mechanisms 
2.6.2.1  -Adrenoceptors 
 
There is a big question about the importance of the adrenergic receptors 
according to the fact there is just few of them in the bladder detrusor. Drugs 
selectively stimulating -adrenoceptors produce a small and variable contractile 
effect. It has been found that only 1A and  1D mRNAs are expressed in the human 
urinary bladder (Malloy et al., 1998). 
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2.6.2.2  -Adrenoceptors 
 
Noradrenaline is released by electrical stimulation of the
 
adrenergic nerves in 
the detrusor tissue. Because -ARs have been shown to predominate over -ARs, the 
response of the normal
 
detrusor to noradrenaline is relaxation. Also, several 
investigators have been able to demonstrate
 
that the human detrusor is able to express 
-, -, as well as-ARs (Andersson & Arner, 2004). 
 
2.6.3 NANC Mechanisms 
 
Muscarinic and adrenergic agonists are not the only ones which affect 
contraction or relaxation of the urinary bladder. In the last group of stimuli, which 
cause a bladder response and which we call non-adrenergic, non-cholinergic 
transmission (NANC), we can find substances such as ATP, nitric oxide, 
neuropeptides (vasoactive intestinal polypeptide, endothelins, tachykinins, 
angiotensins) and prostanoids. 
 
In the current project, the investigations focus on the purinergic responses. For 
this purpose, agonists and antagonists of the purinergic receptors, i.e., purines and 
pyrimidines, are used. 
  
2.6.3.1 ATP on the way to become a pop-star  
 
Adenosine triphosphate has got a very important role as a source of energy for 
living cell. The proofs showing that ATP is actually released to the extracellular 
areas and that specific receptors for ATP exist on the target cells were very important 
findings for the definition of extracellular ATP physiological activity. 
Today, ATP is considered as a valid transmitter in both types of the nerve 
system - centrally and peripherally. Information about the release of ATP by 
exocytosis from the nerve endings cell also exists. However, in non-neuronal cells 
we can probably find different ways of revieling the release of ATP to the 
extracellular areas, respective ATP could be carrier-mediated, by using ATP-binding 
cassette-protein (ABC), an omnipresent family of ATPase. 
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In 1929 adenosine-5’-phosphate (ATP) (a molecule, which is part of the purine 
family and which is composed of heterocyclic base adenine, saccharide ribose and a 
chain of three ionized phosphate groups connected to the saccharide) was identified 
in muscle extracts. 
It was firstly thought that this molecule is responsible for the muscle 
contraction. After few years became obvious three chemically and functionally 
different parts if this bio-molecule were synthetised by independent metabolic ways 
and that the main regulator ATP synthesis was adenosine-5’-diphosphate. Then it 
was demonstrated that ATP is produced during the break down of glucose to lactic 
acid (anaerobic glycolysis) within the citrate cycle and then mainly during oxidative 
phosphorilation. This is of course correlated to the finding that ATP is a source of 
energy, which Lippman later proved by his hypothesis about energy transfer in the 
living cells.  
Very soon ATP was considered as the most important of all the biomolecules, 
according to the new discoveries, since it is an universal source of chemical energy 
for the living cells. And because of this role of ATP is so important, it was then 
thought for many years that this was the only role of ATP. Nobody was thinking that 
there could be other extracellular physiological functions of ATP. The main 
argument why ATP could not have any extracellular function was that a cell would 
never release anything that is so important for their survival. Also the scientists 
considered the size of the molecule by saying that such a big molecule would not be 
able to get through the cell membrane by simple diffusion. However it was soon 
demonstrated that the purines have real extracellular effects on various organs and 
tissues.  
In 1929 Drury and Szent-Gyorgyi lectured for first time about extracellular 
purines being responsible for negative chronotropic effects on the heart, dilatation of 
the heart vessels and of inhibition of spontaneous activity of the intestinal smooth 
muscle. 
 Later on, the effects of purines on gut, bladder, vagina and other visceral 
organs and vascular bed were introduced. It was thought that all these effects are 
caused just by adenosine or adenosine-5’-monophosphate (both breakdown products 
of ATP) but other studies showed that a length of the phosphate chain influences 
activity. Studies also proved that ATP has the largest action of all the purinergic 
compounds.  
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In 1978 Burnstock introduced the thesis, based on his experimental work, that 
purinoceptors concists of two main groups: P1 adenosine selective receptors and P2 
ADP and ATP selective receptors. The presence of the extracellular receptors for 
ATP occurs widely. This kind of receptors is possible to find on neuronal as well as 
on non-neuronal cells. It brings out the question if the ATP is present even in a 
blood. An answer to this question came during the Second World War. When 
injured, cell destruction leads to efflux of the cytoplasmatic adenine compounds to 
the vessel bed, where the really high concentrations of ATP are found. The authors 
then enounced a premise that ATP is part of the biochemical process of the trauma 
shock development. They explained the similarities between shocks caused by low 
blood pressure and ATP.  
Later the effect of high ATP concentrations was explained by fact that while is 
this purine is present extracellulary it causes real changes in permeability of the 
membrane of erythrocytes, which results in huge efflux ions and nucleotides together 
with ATP itself. Soon the same mechanism was described for the smooth muscle 
cells and endothelium (Bodin & Burnstock, 2001). 
 
 
2.6.3.2 ATP as a neurotransmitter 
 
For many years, ATP was thought to be the only source of the energy for cell 
and just this role in the metabolism of the cell was known. But in 1972, Burnstock 
published a theory that ATP is a neurotransmitter. In 1978, he showed the specific 
extracellular receptors for nucleosides (P1) and nucletides (P2) to mediate 
physiological effects of adenosine (P1) and ATP (P2).  
These compounds are very strong signals for exocrine as well as for endocrine 
secretory cells. They also have a specific function as short-term co-transmitters in 
both the central and peripheral nervous systems. It is not just cell growth, 
differentiation and proliferation that the purines and pyrimidines take care of, but 
also for instance the release of hormones, neurotransmitters and cytokines are 
examples of their properties. Now it is also known that they are involved in 
pathological processes such as of the immune system disease, infections and pain, 
neurodegenerative diseases and osteoporosis. There also exist studies about a 
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protective function of purines and pyrimidines in various pathological states for 
example in cancer, ischemia diseases, organ toxicity caused by drugs or radiation, 
trauma, stress and in hemorrhagic shock. These findings about the protective 
functions used to be neglected since all saving procedures were appropriated to 
nonspecific metabolic processes. 
The knowledge of purinergic receptors led us to the issue from the other point 
of view, where we can see effects concerning a lot of different specific mechanisms. 
It helped us A) to understand the mechanisms which are the basics of many 
physiological processes and B) to approximate the principles of different kinds of  
illnesses and contributed to the pharmacological localizing of the right goal for 
treatments (Abbracchio & Burnstock, 1998). 
 
2.6.3.3 Release of ATP  
 
In 1954 Holton and Holton noticed that the venous efflux from a perfused 
rabbit ear showed increased optical density value (at 260 nm) during antidromic 
stimulation of the major auricular nerve. A few years later the same authors came up 
with the conclusion that ATP is released while the same nerve is stimulated. And this 
made  them say that ATP is released from the sensory nerve ending and probably it 
has a role in a chemical transmission (Holton, 1959). 
In 60’s was the release of ATP observed when a muscle or nerve of a frog was 
stimulated by electric field stimulation and this release of ATP was connected with 
the depolarization of the tissue (Abood et al., 1962). Later it was illustrated that ATP 
is synthesized, stored and released from non-adrenergic, non-cholinergic (NANC) 
nerves supplying the intestinal smooth muscle, and the fact the adding of ATP 
actually simulated an effect of nerve stimulation in these muscles, led to the 
suggestion that ATP is a transmitter in non-adrenergic inhibitory nerves in the gut 
(Burnstock et al., 1970).     
Subsequently, it was suggested that ATP could be released as a primary 
neurotransmitter by NANC nerves supplying various vessel beds and visceral organs 
and consequently these nerves were called purinergic nerves. Burnstock also tried to 
find out what the mechanism of the release of ATP out of the cell was. 
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First it was demonstrated in the taenia coli that the molecule of ATP can be 
released by sympathetic nerves together with nor-adrenaline. Later on, in 
parasympathetic nerves, the ATP was proved to work as a co-transmitter with 
acetylcholine in the urinary bladder (Burnstock et al., 1978) and with nor-adrenaline 
in rats in vas deferens, in the tail artery and the aorta. Lastly, ATP was found to be a 
co- transmitter widely used by both nervous systems, centrally in the same way as 
peripherally (Bodin & Burnstock, 2001).    
 
2.7 Purinergic receptors 
 
The classical autonomic transmitters acetylcholine and nor-adrenaline are not 
the only transmitters causing contraction (acetylcholine) and relaxation (nor-
adrenaline), since other transmitters have been shown to take part in urinary bladder 
functional regulation. 
One of these ―other‖ transmitters is ATP. It contributes to the atropine resistant 
contraction by acting on P2X receptor and this contractile response is followed by a 
slower relaxation of the detrusor muscle. There is also a relaxatory response to 
adenosine, a breakdown product of ATP acting on the adenosine P1A2 receptors 
(Giglio et al., 2005a). 
 However, the interaction between the different detrusor receptors may be 
elucidated by how muscarinic receptor activation can inhibit the purinergic 
relaxatory effect. In the case of the need of a prolonged contractile stimulus, the 
breakdown of ATP could oppose the contraction. The relaxatory effect, however, 
caused by exogenous adenosine acting on the adenosine receptor is also inhibited by 
cholinergic stimuli acting on the muscarinic M2 receptor of the detrusor muscle 
(Giglio et al., 2001). This may thus be of functional significance in cases of the need 
of prolonged contractile stimulation. 
During last years, there is an exponential growth of interest of purinergic 
receptors. Mediation of effects by purinergic receptors was first described in 1929 
and the purineceptors were defined in 1978. The difference between P1 (adenosine 
purineceptor)  and P2 (ATP, ADP purineceptors) were discovered also around this 
year, and later A1 and A2 and also P2X and P2Y subclasses of  P1 and P2 
purineceptors were characterized. 
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New subclasses have subsequently been defined, particularly of the nucleotide 
receptors concerning P2T, P2Z, P2U and P2D. Consequently there is confusion how 
to sort out the new findings related to different tissues and purins. 
Studies defining the molecular structures of P2 purinoceptor subtypes are 
constantly appearing. These studies will probably contribute to a clearer picture 
regarding the receptors. They will possibly bring forward some systematic pattern 
according to function and they will most likely be of importance for describing 
pharmacologic properties of drugs with purinergic effects (Abbracchio & Burnstock, 
1994).  
Purines and pyrimidines (ATP, ADP, adenosine and UTP) have specific 
extracellular signalling activity in regulation of various functions in different kinds of 
tissues, both in invertebra as in vertebra. It shows that they seem to have a key role in 
growing, proliferation and gifferenciation of the cell. 
Thus, the activity of extracellular nucleotides and nucleosides (adenosine and 
ATP) was as mentioned previously, first observed in 1929 in a thesis about effect on 
adenosine on mammal heart (Drury & Szent-Gyorgyi, 1929). Thirty years later it was 
found that ATP is released during anti-dromic stimulation of sensoric nerves of 
rabbit ear artery. The NANC compound supplying both the gut and the bladder was 
thus observed and later claimed to be ATP. This suggestion resulted in classification 
of effects by post- junctional receptors for ATP. 
Primary classification of P1 and P2 receptors was based on 4 criterions: 
i. relative effect  of ATP, ADP, AMP and adenosine 
ii. selectivity of antagonists, especially methylxantines (these 
completely antagonise an activity of adenosine but not the activity of 
ATP) 
iii. the modulation of adenylate cyclase with the resulting changes 
at the levels of cAMP inside the cell caused by adenosine, but not by ATP 
            iv. an increased production of prostaglandins caused by ATP which 
adenosine does not evoke. 
This classification has been accepted by the International Union of 
Pharmacology (IUPHAR) Subcommitee for the Nomenclature and Classification of 
Purinoceptors. 
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It was clear that P1 and P2 are two huge receptor families. Now we know that 
there are at least 4 different subfamilies of receptors coupled to G protein- P1 
receptors (adenosine) A1,A2a,A2b,A3 and at least 13 subfamilies of P2 receptors. 
Therefore it was needed to set up other rules defining how to divide the fast 
growing group of P2 receptors. Now the group is divided to two smaller- P2Y and 
P2X subtypes. These can cause vasoconstriction, vasodilatation but they respond 
differently to synthetic analogs of ATP. Subtypes have been found, which do not 
match any of these groups. Since so many of these appeared, Abbracchio and 
Burnstock came with a new nomenclature (Abbracchio & Burnstock, 1998). 
 
1. Two purinoceptors families are determined: i. P2X ligand 
gated family and ii. P2Y coupled to G protein 
2. 4 subclasses of P2X were identified: P2X1, P2X2, P2X3 and 
P2X4 
3. Different receptors coupled to G protein and named P2 should 
be included in subclass of P2Y family. 
These are: 
 i. P2Y1 represents the recently cloned P2Y receptor (clone 803) from 
chick brain 
      
 ii. P2Y2 represents the recently cloned P2U (or P2N) receptor from 
neuroblastoma, human epithelial and rat heart cells 
 
 iii. P2Y3 represents the recently cloned P2Y receptor (clone 103) from chick 
brain that resembles the former P2t receptor 
 
 iv. P2Y4–P2Y6 represent subclasses based on agonist potencies of newly 
synthesised analogues 
  
 v. P2Y7 represents the former P2D receptor for dinucleotides 
 
This new classification of P2 purinoceptors is very similar to the one 
developing for the receptors of other major transmitters, such as acetylcholine, -
aminobutyric acid, glutamate and serotonin, where two main families are recognized 
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– one connected to the fast transmission (receptors directly linked to the ion channel) 
and the second one mediating slower responses by G protein coupled receptors.  
A scientific discussion is mots likely to occur on the matter of the numbering 
of the different receptor subtypes within the P2X and P2Y families. But many 
authors believe that this new way of defining the receptors for nucleotides according 
to agonist potency, transduction mechanism and molecular structure will give a more 
order and logical approach to adjustment new findings (Abbracchio & Burnstock, 
1994). 
 
 
 
2.7.1 Purinoceptors subtypes 
2.7.1.1 P1 purinoceptors 
 
Four subtypes of P1 receptors have been cloned, A1, A2A, A2B and A3 and all of 
these P1 receptors are G protein coupled. They have seven putative transmembrane 
domains of hydrophobic amino acids. Each of these domains is composed of 21-28 
amino acids and makes a structure of an -helix. This long protein has two ends - the 
N- terminal and the C- terminal. The N-terminal is situated on the extracellular side 
and the C- terminal on the cytoplasmatic side of the membrane. The intracellular part 
of the receptor connects to the G protein. When this happens, the transduction of the 
signal is performed. 
The parts in the transmembrane regions are of great importance for the ligand 
binding. This part is also the determinant for the receptor specifity. On the other 
hand, the extracellular loops, the C-terminal and the N- terminal do not seem to be 
involved in ligand recognition (Burnstock, 2006b). 
A1 and A3 receptors preferably interact with members of the
 
Gi family and 
inactivate adenylate cyclase to decrease the production
 
of cAMP, whereas A2a and 
A2b receptors are coupled to Gs and
 
stimulate cAMP production. All four receptors 
activate phospholipase
 
C (PLC), resulting in inositol 3,4,5-trisphosphate (IP3) 
production
 
and increased cytoplasmic Ca
2+
, and can also stimulate
 
mitogen-activated 
protein kinase cascades (Schulte & Fredholm, 2003). 
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2.7.1.1.1 Review of main distribution, agonists and antagonists  
for the P1 receptors (Tab. 2.1: adapted from Burnstock, 2006b) 
 
 
Re
ceptor 
Main distribution Agonists Antagonists 
A1 Brain, spinal cord, testis, 
heart, 
Autonomic nerve terminals, 
bladder 
CCPA, CPA DPCPX, CPX, 
XAC 
A2
A 
Brain, heart, lungs, spleen CGS 21680 KF17837, 
SCH58251 
A2
B 
Large intestine, bladder NECA Enprofylline 
A3 Lung, liver, brain, testis, heart DB-MECA,DBX 
MR 
MRS1222, L-
268,605 
 
Tab. 2.1: CCPA, 2-chloro-N 6-cyclopentyladenosine; CPA,N 6-cyclopentyladenosine; CPX, 8-
cyclopentyl-1,3-dipropylxanthine; XAC, xanthine amine congener;NECA, N-
ethylcarboxamidoadenosine;DBX RM, 1,3-dibutylxanthine-1-riboside-5′-N-methylcarboxamide; 
DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; 
 
 
An investigation to explore the role of A1-purinegic receptors according to the 
adenosine-5’-triphosphate (ATP) and diadenosine tetraphosphate (AP4A)-induced 
contractions was performed by Khattab et al. The presence of A1-purinoceptors 
mediating contraction in response to selective A1-purinoceptor agonists was then 
demonstrated on isolated rings of rat urinary bladder (Khattab et al., 2007). On the 
other hand there are some studies indicating an opposite view in comparison with  
Khattab’s statement. Rubino showed that P1- A2B  subtype lowers the vascular tone 
in the rat isolated mesenteric arterial bed. In preparations at basal tone, adenosine 
lacked vasoconstrictor actions, while ATP elicited dose-dependent vasoconstrictor 
responses. When the tone of preparations was raised by adding methoxamine to the 
perfusate, adenosine and its stable analogue, 2-chloroadenosine (2-CADO) elicited 
dose-dependent vasodilation (Rubino et al., 1995). 
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Also an experiment done by Mathie supported the suggestion about relaxation. 
This study was carried out in order to identify the receptor being responsible for 
adenosine-induced dilatation of the hepatic arterial vascular bed. They found, by 
adding adenosine and its more stable analogues, you actually get a dilatation of the 
rabbit hepatic arterial bed as a result from activation of P1-purinoceptors of the A2 
subtype. They showed that there is significant attenuation of the vasodilatation to 
adenosine and analogues in the presence of the P1- purinoceptor antagonist 8-
phenyltheophylline (Mathie et al., 1991). That adenosine causes a relaxation has 
been also suggested in study about purinergic responses in urinary bladder (Giglio et 
al., 2001). It seems then that we cannot aver that we get a relaxatory response by 
stimulating generally P1 adenosine receptors but we can claim some subtypes of P1 
adenosine receptors give us a relaxation. 
 
Western
 
blot analysis of urinary bladder tissues has established that all four 
adenosine receptors
 
(A1, A2a, A2b, and A3) are expressed in the urothelium. A1
 
receptors are prominently localized to the apical membrane
 
of the umbrella cell layer, 
whereas A2a, A2b, and A3 receptors
 
are localized intracellularly or on the basolateral 
membrane
 
of umbrella cells and the plasma membrane of the underlying
 
cell layers. 
Adenosine is released from the urothelium,
 
which is potentiated 10-fold by stretching 
the tissue. The urothelium
 
is responsive to adenosine and adenosine may increase 
exocytosis
 
in the urothelium. 
The agonist/antagonist studies have indicated that
 
the activity of A1 receptors 
may dominate at the mucosal
 
surface, with some contribution from A2A receptors. In 
contrast,
 
A2A receptors may dominate at the serosal surface, but with a
 
significant 
contribution by A1 and possibly A2B receptors (Yu et al., 2006). 
 
2.7.1.1.2 Adenosine  
  
ATP generates contraction. This contraction is followed by relaxation, which 
has been suggested to depend on the metabolite of ATP, adenosine, stimulating 
inhibitory P1 purinoceptors (Giglio et al., 2001). 
Adenosine
 
is generated within the cell from the hydrolysis of S-adenosyl-L-
homocysteine
 
and is also formed both extracellularly and intracellularly
 
from the 
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hydrolysis of ATP, ADP, AMP, or cAMP (Jackson & Raghvendra, 2004). Also it is a 
potent vasodilator in most vascular beds. It has been shown in many studies that this 
nucleoside plays a significant role in the local, metabolic regulation of blood flow in 
various organs. The dilatation induced by adenosine is mediated by the activation of 
A2A receptors and the subsequent production of NO and opening of  K
+
-ATP 
channels (Hein et al., 2005). 
In the bladder, adenosine, acting through
 
cell surface receptors, may also act in 
an autocrine/paracrine
 
manner to regulate exocytosis in the umbrella cell layer both
 
in response to, and independently of, bladder filling. One particular function
 
for 
adenosine has been identified in the urothelium, namely the modulation of exocytic 
traffic. However, it is likely that adenosine regulates other functions of
 
the 
urothelium and the bladder including ion transport, urothelial-afferent
 
nerve 
signaling, and bladder contraction (Yu et al., 2006). 
 
2.7.1.2 P2X purinoceptors 
  
P2X receptors are honourable members of ligand gated ion channel receptor 
family (Fig.2.7). P2X receptor subtypes are characterized by two transmembrane 
domains, one short intracellular N- and C-termini and an extensive extracellular loop 
with conservation of ten cysteines (Burnstock, 2001). 
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Fig 2.7: Ligand gated ion channel receptor (adapted from: 
http://www.nature.com/nature/journal/v442/n7102/images/nature04886-
f2.2.jpg) 
  
Changes in the sensory input from the bladder (i.e., bladder hypersensitivity)
 
play an important role in the development of interstitial cystitis (IC). IC is associated 
with an increased release of adenosine
 
triphosphate (ATP) from bladder urothelial 
cells and ATP is also released from the bladder urothelium in response
 
to stretch or 
bladder distension (Vlaskovska et al., 2001). Interactions between the urothelium
 
and 
bladder nerve terminals are thought to regulate micturition
 
and nociception 
 
and ATP 
and P2X receptors have been implicated in bladder nociception (Ford et al., 2006). 
The bladder inflammation produces hyperexcitability
 
and sensitizes bladder 
neurons. This hypersensitivity is associated with an increased
 
expression and/or 
properties of homomeric P2X3 and heteromeric
 
P2X2/3 receptors in lumbosacral and 
thoracolumbar bladder neurons, respectively.
 
The altered P2X receptor expression 
accounts for greater current
 
density in response to purinergic agonists, and is likely to 
contribute
 
to the slowed desensitization kinetics of the slow desensitizing
 
current 
after bladder inflammation. Findings also suggest that the altered expression of P2X 
receptors contribute
 
to the enhanced responses of bladder neurons during cystitis 
(Dang et al., 2008). 
2.7.1.2.1 Review of main distribution, agonists and antagonists  
for the P2X receptors (Tab. 2.2: adapted from Burnstock, 2006b) 
 
 
Re
ceptor 
    Main distribution Agonists Antagonis
ts 
P2
X1 
Smooth muscle, platelets, 
cerebellum,  
dorsal horn spinal, 
neurons 
α,βmeATP = ATP = 
2meSATP 
(rapid desensitization) 
TNP-ATP, IP5I, 
NF023 
P2
X2 
Smooth muscle, CNS, 
retina,  
autonomic and sensory 
ATP ≥ ATPγS ≥ 
2meSATP >> α,βmeATP 
(pH + zinc sensitive) 
Suramin, 
PPADS 
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ganglia 
P2
X3 
Sensory neurons, 
sympathetic neurons 
2meSATP ≥ ATP ≥ 
α,βmeATP 
(pH + zinc sensitive) 
TNP-ATP, 
suramin, 
PPADS 
P2
X4 
CNS, testis, colon ATP >> α,βmeATP - 
P2
X5 
Proliferating cells in skin, 
gut, 
bladder, thymus, spinal 
cord  
ATP >> α,βmeATP Suramin, 
PPADS 
P2
X6 
CNS, motor neurons in 
spinal cord 
(does not function as – 
Intrinsic ion channel 
homomultimer) 
- 
P2
X7 
Apoptotic cells in 
immune cells, pancreas, 
skin 
BzATP > ATP ≥ 
2meSATP >> α,βmeATP 
KN62, KN04, 
Coomassie 
brilliant blue 
 
   
Tab. 2.2: α,βme-ATP, α,β-methylene ATP; 2meSATP, 2-methylthioATP; BzATP, 2′,3′-O-(4-
benzoyl-benzoyl) ATP; Ins(1,4,5)P3, inositol (1,4,5)-trisphosphate; IP5I, diinosine pentaphosphate; 
PPADS, pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; RB2, Reactive blue 2; TNP-ATP, 
2′,3′-O-(2,4,6-trinitrophenyl) adenosine 5′-triphosphate; 
 
 
 
 
 
2.7.1.3 P2Y purinoceptors  
 
P2Y receptors, which, in common with other G protein coupled receptors (Fig. 
2.8), have seven transmembrane domains, have an extracellular N-terminus and 
intracellular C-terminus. The conservation between the different subtypes is greatest 
in the transmembrane domains, while the C-terminus shows the greatest diversity 
(Burnstock, 2001). 
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Fig. 2.8: G protein coupled receptor (adapted from: 
http://journals.prous.com/journals/dof/19992407/html/df240759/images/Yerxa  
2.gif) 
 
 
2.7.1.3.1 Review of main distribution, agonists and antagonists  
for the P2Y receptors (Tab. 2.3: adapted from Burnstock, 2006b) 
 
 
Re
ceptor 
  Main distribution Agonists Antagonists 
P2
Y1 
Epithelial and 
endothelial cells, 
platelets, 
immune cells, osteoclasts 
2meSADP > 2meSATP 
= ADP > ATP 
MRS2279, 
MRS2179 
P2
Y2 
Immune cells, epithelial 
and endothelial cells, 
UTP = ATP Suramin 
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kidney tubules, 
osteoblasts 
P2
Y4 
Endothelial cells UTP = ATP RB2, PPADS 
P2
Y6 
Some epithelial cells, 
placenta, T cells, thymus 
UDP > UTP >> ATP RB2, PPADS, 
suramin 
P2
Y11 
Spleen, intestine, 
granulocytes 
ARC67085MX > BzATP 
≥ ATPγS > ATP 
Suramin, RB2 
P2
Y12 
Platelets ADP ARC67085MX, 
ARC69931MX 
P2
Y13 
Spleen, brain, lymph 
nodes, bone marrow 
ADP = 2MeSADP >> 
ATP and 2MeSATP 
 
P2
Y14 
Placenta, adipose tissue, 
stomach, intestine,  
discrete brain region 
UDP glucose = UDP-
galactose  
 
 
Tab. 2.3: PPADS, pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; BzATP, 2′,3′-O-(4-benzoyl-
benzoyl) ATP; 2meSATP, 2-methylthioATP; RB2, Reactive blue 2; 
 
2.7.2 Purinergic receptors and pain 
 
The involvement of ATP in the initiation of pain was recognized in the early 
60’s. It was Burnstock who put forward a unifying purinergic hypothesis for the 
initiation of pain by ATP acting via P2X3 and P2X2/3 receptors associated with 
causalgia, reflex sympathetic dystrophy, angina, migraine, pelvic and cancer pain. 
This has been followed by an increasing number of papers expanding this concept for 
acute, inflammatory, neuropathic and visceral pain. A hypothesis was proposed that 
purinergic mechanosensory transduction occurs in visceral tubes and sacs, including 
the ureter, bladder and gut, where ATP released from epithelial cells during 
distension acts on P2X3 homomultimeric and P2X2/3 heteromultimeric receptors on 
subepithelial sensory nerves to initiate impulses in sensory pathways to pain centres 
in the CNS (Burnstock, 2006b). 
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2.7.3 Purinergic receptors and inflammation 
 
P2X7 and P2Y1 and P2Y2 receptors located on inflammatory and immune cells 
play a pivotal role in inflammation and immunomodulation. ATP and its breakdown 
product adenosine are released at sites of inflammation. ATP is involved in the 
development of inflammation through a combination of actions: release of histamine 
from mast cells, provoking production of prostaglandins, and the production and 
release of cytokines from immune cells. In contrast, adenosine exerts anti-
inflammatory actions (Burnstock, 2006b).  
  
Inflammatory urinary bladder 
 
It was shown that mice with blocked P2X3 receptors exhibited reduced 
inflammatory pain and marked urinary bladder hyporeflexia with reduced voiding 
frequency and increased voiding volume, suggesting that P2X3 receptors are 
involved in mechanosensory transduction underlying both inflammatory pain and 
physiological reflexes (Cockayne et al., 2000). Recent studies have shown significant 
increase in the release of ATP from the urothelium in different animal models of 
interstitial cystitis as well as in interstitial cystitis in humans; in response to stretch in 
the cat model, in the cyclophosphamide mouse model as well as from urothelial cells 
from patients with interstitial cystitis. Release of ATP from urothelial cells with 
hypo-osmotic mechanical stimulation was increased by over 600% in inflamed 
bladder from cyclophosphamide-treated animals, which was inhibited by botulinum 
toxin (Burnstock, 2006a). Furthermore, an increase in stretch-evoked urothelial 
release of ATP has been reported from porcine and human bladders with sensory 
disorder (urgency) compared with normal bladders (Kumar et al., 2004). 
 44 
3 Aims 
 
The aim of the thesis is to investigate the presence and function of selected 
purinergic receptor subtypes, namely P1A1 and P2X1, in the urinary bladder of the 
rat. Three questions were raised:  
1. Do these receptors exist in the urinary bladder? 
2. If they do exist, where are they located?   
3. Do their expression, as well as location change during the inflammatory 
process of the urinary bladder? 
The aim for the functional studies is to describe if the bladder reacts differently 
according to this receptor change during the inflammation. This investigation should 
also show us what is the role of these receptors. 
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4 Methods and Materials 
4.1 Immunohistochemistry 
4.1.1 Introduction of the method 
 
Immunohistochemistry is used for the localization of antigens or proteins in 
tissue sections by employing labeled antibodies as specific reagents through antigen-
antibody interactions that are visualized by a marker such as fluorescent dye, 
enzyme, or colloidal gold. Since immunohistochemistry involves specific antigen-
antibody reaction, it has an apparent advantage over traditionally used special 
enzyme staining techniques that identify only a limited number of proteins, enzymes 
and tissue structures. Therefore, immunohistochemistry has become a crucial 
technique and widely used in many medical research laboratories as well as clinical 
diagnostics. There are numerous immunohistochemistry methods that may be used to 
localize antigens. The selection of a suitable method should be based on parameters 
such as the type of specimen under investigation and the degree of sensitivity 
required. 
An important part of immunohistochemistry is the tissue preparation, such as 
fixation and sectioning. It is essential to ensure the preservation of tissue architecture 
and cell morphology, prompt and adequate fixation. The most common fixatives 
used for immunohistochemistry are 4% paraformaldehyde in 0.1M phosphate buffer, 
2% paraformaldehyde with 0.2% picric acid in 0.1M phosphate buffer, 4% 
paraformaldehyde with 0.05% glutaraldehyde (TEM immunohistochemistry), 4% 
paraformaldehyde, 0.2% periodate and 1.2% lysine in 0.1M phosphate buffer (PLP 
fixative). Sectioning is provided by vibratome.  
The demonstration of many antigens can be significantly improved by the 
pretreatment with the antigen retrieval reagent that break the protein cross-links 
formed by formalin fixation and thereby uncover hidden antigenic sites. Microwave 
Oven, Pressure Cooker and Steamer are the most commonly used heating devices. 
Citrate buffer of pH6.0 is the most popularly used retrieval solution and is suitable 
for most of antibody applications. Next step in immunohistochemistry is a non-
specific background blocking. The main cause of non-specific background staining is 
non-immunological binding of the specific immune sera by hydrophobic and 
 46 
electrostatic forces to certain sites within tissue sections. This form of background 
staining is usually uniform and can be reduced by blocking those sites with normal 
serum. The solution for eliminating endogenous peroxidase activity is by the 
pretreatment of the tissue section with hydrogen peroxide prior to incubation of 
primary antibody. 
In the immunohistochemistry, as well as in other experiments through the 
whole scientific field, controls are needed for comparisons. A positive control serves 
to test a protocol or procedure and make sure it works. A negative control serves to 
test the specificity of an antibody involved. First, no staining must be shown when 
omitting primary antibody or replacing an specific primary antibody with normal 
serum (must be the same species as primary antibody). This control is easy to 
achieve and can be used routinely in immunohistochemical staining. 
There are two principal methods in immunohistochemistry, direct and indirect. 
The direct method is an one step staining method, and involves a labelled antibody 
(i.e. FITC conjugated antiserum) reacting directly with the antigen in tissue sections.  
The indirect method involves an unlabelled primary antibody (first layer),which 
reacts with tissue antigen, and a labelled secondary antibody (second layer) reacting 
with primary antibody (Note: The secondary antibody must be against the IgG of the 
animal species in which the primary antibody has been raised).  
Many indirect methods are used for the localization of proteins. For example 
PAP (peroxidise anti- peroxidise method), ABC (Avidin-Biotin Complex) method, 
LSAB (Labeled StreptAvidin Biotin) method or various polymeric methods. 
 
Avidin-Biotin Complex (ABC) Method:   
  
ABC method is standard IHC (use the abbreviation all the time and explain it 
the first time or avoid it constantly) method and one of widely used technique for 
immunhistochemical staining (Fig. 4.1). Avidin, a large glycoprotein, can be labelled 
with peroxidase or fluorescein and has a very high affinity for biotin. Biotin, a low 
molecular weight vitamin, can be conjugated to a variety of biological molecules 
such as antibodies.  
  
The technique involves three layers. The first layer is unlabelled primary 
antibody. The second layer is biotinylated secondary antibody (secondary antibody, 
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Santa Cruz ABC- kit). The third layer is a complex of avidin-biotin peroxidise (AB 
enzyme reagent, Santa Cruz ABC- kit). The peroxidase is then developed by the 
DAB (peroxidise substrate, Santa Cruz ABC- kit) or other substrate to produce 
different colorimetric end products (World IHC, 2007).  
 
Fig. 4.1: ABC- method 
 
4.1.2 Materials 
  
The following solutions and compounds were used in the current study: 
Xylene; ethanol- 99.5%, 95%, 85%, 85%, 70%; deionised water; TBS (4 l; 
pH= 7.5; 52.9 g Trizma- HCl; 7.8g Trizma-Base; 36g NaCl); citrate buffer (1 l; pH= 
6.0; 10mM; 2.1 g citric acid of MW= 210.14 g/mol; 0.97 g NaOH or 6 ml 2M 
NaOH); H2O2 ( 0.03%); BSA(bovine serum albumin); primary antibody diluted in 
1% BSA in TBS (125 µl of the antibody diluted 1:10, 1125 µl TBS, 1.25 mg BSA); 
1% BSA in TBS (1125 µl TBS, 1.25 mg BSA);  Santa Cruz ABC- kit, hematoxylin; 
glue  
4.1.3 Immunohistochemistry procedure 
 
If we have got the glasses with two thin slices of urinary bladder ready on each 
glass we can start to run the immunohistochemistry procedure. 
This experiment takes two days. First day the paraffin that the bladder slices 
are fixed in is removed and the membranes are ruptured for enabling binding of the 
primary antibody. This is followed by overnight incubation and on the second day 
the incubating with antibody and staining is proceeded. There are two slices on each 
glass. One is marked as a positive and the other one as a negative control. To have a 
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negative control is necessary because it shows selectivity of the primary antibody. 
The more accurate, the more correct result will we get at the end by comparing the 
negatives with the positives.   
Protocol 
DAY ONE 
 
1. The sections were incubated at 60°C for 60 minutes which 
made the paraffin soft. 
 
2. Second step is the deparaffination itself. The glasses need to be 
rinsed twice for 30 minutes in xylene (twice means after first 30 minutes the 
glasses are emerged from the pot filled by the liquid and merged back for 
another 30 minutes), then twice for 5 minutes in 99.5% ethanol, twice for 5 
minutes in 95% ethanol, for 5 minutes in 85% ethanol and finally for 5 
minutes in 70% ethanol. The glasses need to be checked if all paraffin is 
gone. If not, this step has to be repeated. 
 
3. The glasses were rinsed under flowing deionised  water for 10 
minutes so residues of ethanol and paraffin are washed out. The glasses are 
rinsed twice for 5 minutes in TBS. The TBS is used almost after every step. It 
is supposed to wash out solutions used in previous step, inactivate the 
reactions which had been going on and get the sample to the ―normal state‖.  
 
4. Then the glasses need to be rinsed in citrate buffer for 5 
minutes. Boiling the samples in citrate buffer in a microwave oven four times 
for 6 minutes follows this. Every time is the pot with the glasses refilled by 
the citrate buffer to prevent it from boiling away. The sections must not boil 
away. Then the glasses are supposed to cool in citrate buffer for 30 minutes. 
 
5. The glasses are washed in TBS twice for 5 minutes. 
 
6. Next step is blocking the endogen peroxidise by adding 0.03% 
H2O2 for 30 minutes.    
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7. The glasses are washed again in TBS twice for 5 minutes. 
 
8.   The area around each section was demarcated with a 
hydrophobic pen. The glasses have to be let to get dry a bit. Then the 
blocking of non-specific background using 5% BSA in TBS for 30 minutes 
has to be done.   
 
9. Only this step varies the positives and negatives samples from 
each other. That is why it needs to be done very carefully. First the positive 
and negative sample on each of the glasses has to be marked. The positives 
are then incubated over night with primary antibody diluted in 1% BSA in 
TBS. The negative controls on the other hand are incubated just in 1% BSA 
in TBS (1125 µl TBS + 1.25 mg BSA). The box used for incubation has to be 
closed and filled by water so the water can not touch the glasses but it can 
prevent the sections from becoming dry. 
 
 
DAY TWO  
 
1. The Santa Cruz ABC-kit was used for binding the secondary 
antibody and staining the samples. The ABC-kit has to suit to the primary 
antibody, which was used the previous day. According to the manual the 
secondary antibody, AB enzyme reagent and peroxidise substrate were 
mixed. 
 
2. The glasses were washed in TBS twice for 5 minutes. The best 
way how to prevent mixing two drops on the glass together is by removing 
the drop using the automatic pipette. It does not really matter if they mix 
during other steps of the whole procedure but  ―the step 9 of the day one‖ and 
this step are only two points where is needed to be precise and treat positive 
and negative control just by what they are supposed to be.   
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3. The glasses are ready now to be incubated  with secondary 
antibody for 30 minutes in the same box under the same conditions they were 
incubated during the night.  
 
4.  They were washed twice in TBS for 5 minutes. 
 
5. Then the incubation with AB enzyme reagent for 30 minutes 
was proceed.  
 
6. The glasses were washed again in TBS twice for 5 minutes. 
 
7. The sections were incubated in peroxidise substrate until they 
got brown. Recommended time is 5 minutes.  
 
8. The samples were then carefully rinsed in flowing deionised 
water for 10 minutes. 
 
9. Next step was staining with hematoxylin until stained enough, 
usually between 2-4 minutes. 
 
10. The glasses were rinsed in 37ºC  water until they became blue. 
 
11. The samples now need to be merged to the ethanol in 
increasing concentrations and in xylene in the end for 10 minutes in each. 
 
12. When almost dry, the sections had to be glued and covered by 
the cover glass.  
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4.2 In vitro functional studies 
4.2.1 Rats 
  
Male rats of the Sprague-Dawley strain with the weight of 250-300 g were 
used in the current thesis. The study was approved by to local ethical committee of 
Göteborg University. 
 
4.2.2 Urinary bladder strip preparation 
 
The rats were anaesthetized with carbon dioxide and then killed with overdose 
of the same gas. The urinary bladder was removed. After cutting and opening the 
bladder two or three strips 6x2 mm big were excised from the middle of the organ. In 
order to keep the bladder wet, it was constantly kept in Krebs bicarbonate solution. 
For the contraction experiments, organ bathes were used. The strips were 
fastened between two steel rods. One of these two rods was adjustable. The organ 
bath containing the strip and the two steel rods device was filled by Krebs 
bicarbonate solution of the following composition: deionised water, NaCl 6.9g/l, KCl 
0.34g/l, KH2PO4 0.16g/l, MgSO4 0.14g/l, NaHCO3 2.10g/l, glucose 0.99g/l, the 
solution was bubbled by gas mixture of  95% O2 and 5% CO2 for at least 45 minutes 
before CaCl2 0.18g/l was added and then it was bubbled by the same gas all the time 
to keep a stable and neutral pH. The temperature was kept at 37 ºC by a thermostat. 
The strips were pre-stretched to a tension of 10 mN and left to equilibrate for 45 
minutes. It resulted to fluent relaxation and the strips got stabilised about 3- 5 mN. 
After 45 minutes all strips were treated by ―high potassium krebs‖ (124 mM; 
4.41g KCl in 0.5 l krebs bicarbonate solution), which was used as a reference 
solution employed in each experiment. When the maximum contraction was reached, 
the high potassium krebs was washed out and the bathes were refilled by the ―normal 
physiologic‖ bicarbonate krebs. Then the tension has to be stabilised on 3- 5 mN 
again if needed and after at least 20 minutes the experiment started.  
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4.2.3 Adenosine effect 
 
For functional studies of P1A1 receptors, a concentration of adenosine (its 
agonist) was used since it gives the most suitable response. This response shows a 
significant, rather sharp and relatively fast relaxation. To find the appropriate  
concentration of adenosine giving relaxation, a contractile response has to be present. 
Therefore, when the relaxatory experiment is performed, the tissue strips were 
exposed to ―low potassium krebs‖. The concentration of this solution is ―50mM in 
bath‖ (1.86g KCl in 10ml krebs bicarbonate solution). It means the real concentration 
of the solution in a tube is actually 50 times higher. Thus, after adding 0.5 ml of it in 
to the organ bath of 25 ml, the solution is diluted to 50mM. By pre-contracting the 
tissue we wanted to get a tension around 8 and 10 mN, so when relaxatory agent is 
added the tissue would have a space to relax. In order to get the right precontractile 
value, low potassium krebs was sometimes needed to be added in somewhat higher 
concentrations. Right after the administration of the low potassium krebs, a 
concentration of phentolamine and propranolol (both in concentration of  
10
-5
mol/l) were added to block possible adrenergic responses.    
The tissue was let to be pre-contracted for 30 minutes, then the adenosine in 
increasing concentrations was added within 1-2 minutes (after minimum response 
was reached). The used concentrations of adenosine were 10
-7
, 5x10
-7
, 10
-6
, 5x10
-6
, 
10
-5
, 5x10
-5
, 10
-4 
mol/l. The procedure was repeated once again after washing the 
baths. 
 
4.2.4 Determination of response to adenosine caused by P1A1 
receptors in healthy and cystitis rats  
  
When the effects of antagonists were examined, the protocol described above 
was repeated four times, every time a new antagonist was added. After phentolamine 
and propranolol it was a reversible antagonist of the muscarinic receptors 4-DAMP 
of concentration 10
-5
 mol/l. The next round was the relaxation performed with all 
previous antagonist plus reversible selective P2 purinoceptors antagonist PPADS of 
10
-4
 mol/l. In the final round five antagonists were used including DPCPX, an 
irreversible specific P1A1 antagonist of concentration 10
-5
 mol/l. All drugs were 
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administrated in volume 125µl. The incubation time for all antagonists was 20 
minutes. The very same procedure was performed with the bladder strips from 
control and cystitis rats.  
4.2.4.1 Cystitis rats 
 
Inflammation of the urinary bladder was induced by the pre-treatment with 
cyclophosphamide. The rats were given cyclophosphamide in concentration 100 
mg/kg i.p. in combination with the anaesthetic buprenorphinum 10 µg/kg i.m. The 
urinary bladder was removed 60 hours later (Giglio et al., 2005b).  
 The compound N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-
oxide (Cyclophosphamide, C7H15Cl2N2O2P,
, 
261.085) is a drug used for treatment of 
various types of cancer or autoimmune disorders. One of its many side effects is that 
it actually cause a cystitis and for this ―property‖ it is used for pre- treatment for 
inducing inflammation in the ―cystitis rats‖ group in the experiments showed in this 
project.  
 
 
4.2.5 Determination of relaxatory response caused by P1A1 using 
electric field stimulation (EFS) in healthy and cystitis rats 
 
A contraction experiment using electric field stimulation (EFS) was run in the 
similar way as the previous ones. The procedure of the strip preparation is the same.  
No pre-contraction was performed in these experiments, but ―high potassium krebs‖ 
for the reference response was used. After this step the baths were washed, refilled 
with physiological krebs and the strips had to equilibrate for 20 minutes before the 
first EFS was performed. 
First the tissue was stimulated three times within 20 minutes with no antagonist 
present at a frequency of 40 Hz (this frequency elicits the maximal response as 
shown in previous preparatory experiments). Then the antagonists were added all in 
the volume of 125 µl as in the ―agonist experiments‖. 
Propranolol and phentolamine were first added to the organ baths and after 20 
minutes the strips were stimulated by the electric field. Without any rewashing 4-
DAMP was put on and again incubated for 20 minutes in presence of the three 
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antagonists, before another measuring the tone. Then PPADS was added and lastly 
DPCPX. 
The baths were then washed. When the experiments were repeated within the 
same strips, the antagonists had to be added in another way of the rounds, starting 
with DPCPX since it is only irreversible antagonist of the used ones. It means this 
kind of experiment can be performed just twice with the same strips while using 
irreversible antagonist.   
 
4.2.6 Materials 
 
For immunohistochemistry the following materials and substances were used: 
ABC Staining system sc-2018 for use with rabbit primary antibody (Santa Cruz 
Biotechnology, USA), Anti-P2X1 Purinergic Receptor- developed  in rabbit (Sigma, 
Sweden), Anti-P1A1 Purinergic Receptor- developed in rabbit (Sigma, Sweden), 
Mayer´s hematoxyline (Histolab, Göteborg, Sweden). 
Substances used in contraction experiments were used as follows: 9-β-D-
Ribofuranosyladenine, Cell Culture Tested (Adenosine, C10H13N5O4, 267.24,Sigma, 
Sweden),2-[N-(3-Hydroxyphenyl)-p-toluidinomethyl]-2-imidazolidine hydrochloride 
(Phentolamine, C17H19N3O · HCl, 317.81, Sigma, Sweden), DL-Propranolol-[4-
3
H] 
hydrochloride (Propranolol, C16H21NO2 · HCl, 295.80, Sigma), 4-Diphenylacetoxy-
N-methylpiperidine methiodide, powder (4-DAMP, C21H26INO2  451.34, Sigma), 
Pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid) tetrasodium salt hydrate, 
solid, ≥98% (HPLC) (PPADS, C14H10N3Na4O12PS2 · xH2O, 599.31 (anhydrous 
basis), Sigma), 1,3-Dipropyl-8-cyclopentylxanthine, solid (DPCPX, C16H24N4O2, 
304.39, Sigma). Chemical structure of used antagonists shows Fig. 4.2. 
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Fig. 4.2: Chemical structure of used antagonists 
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5 Results 
 
5.1 Immunohistochemistry 
 
5.1.1  P1A1 receptors 
  
The staining colour showing presence of P1A1 receptors is brown. In the 
negative samples it is clear the primary antibody was highly selective to P1A1 
receptors since there was a lack of brown colour at all (pictures A, C, E, G).  
Brown areas in the positive saline samples (Fig. 5.1) show where the P1A1 
receptors are located in the healthy urinary bladder (pictures B, D). We can see that 
all parts of urinary bladder (urothelium, sub- urothelium and muscle) is brown and 
with about the same colour intensity. Thus, P1A1 receptors seem to be present in the 
urinary bladder just everywhere, and the intensity shows density or frequency of the 
receptors in different areas. In the case of P1A1 receptors the frequency of 
appearance is thus the same in urothelium, sub- urothelium and in the muscle. 
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Fig. 5.1: Immunohistochemical labeling of bladders negative controls (A, C) and positive saline samples (B, D). 
All sections are counterstained with hematoxyline. Right column (B, D) shows the staining for P1A1 receptors. 
The pictures all show a cut through whole urinary bladder with urothelium on the left, sub- urothelium in the 
middle and muscle on the right side.  
 
The appearance of the receptor seemed to be different in inflamed urinary 
bladders as showed in figure 5.2. Even here it is obvious staining was specific to 
P1A1 receptors since there was no brown colour in the negative samples (picture E, 
G). Also the cystitis bladder (pictures F, H) was coloured brown compare to the 
negatives. The frequency of the brown areas was the same in urothelium, sub- 
urothelium and in the muscle, but intensity of brown colour differs comparing to 
saline positives (pictures B, D). This led us to the conclusion that there exist P1A1 
receptors and that they are present in all parts of the bladder but their amount 
decreases during inflammatory process.  
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Fig. 5.2: Immunohistochemical labeling of bladders negative controls (E, G) and positive cystitis samples (F, H). 
All sections are counterstained with hematoxyline. Right column (F, H) shows the staining for P1A1 receptors. 
The pictures are situated all the same direction so urothelium would be on the left side and muscle tissue on the 
right. Also picture H  shows typical view of cystitis in urinary bladder: incrassate urothelium- consisted from 
more than one layer of urothelium cells, increased connective tissue and vacuols in sub- urothelium.  
 
 
 
5.1.2 P2X1 receptors       
 
According to the specific staining for P2X1 receptors (Fig.5.3 and 5.4), these 
are mainly localized to the muscle tissue but also to the urothelium of the healthy rat 
urinary bladder (Fig. 5.3). 
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Fig. 5.3: Immunohistochemical labeling of bladders negative controls (a, c) and positive saline samples (b, d). 
All sections are counterstained with hematoxyline. Right column (b, d) shows the staining for P2X1 receptors. 
The pictures show the cut through whole bladder, on the left it is an urothelium, sub-urothelium and connective 
tissue and muscle on the right side of the each picture. 
 
 
However, the same observation was made even in the cystitis urinary bladder 
sections (Fig. 4). The brown staining shows where the P2X1 receptors are present and 
the intensity of the colour the density of the receptors. The brown colour intensity 
(comparison of right columns of Fig. 5.3 (b, d) and Fig. 5.4 (f, h, j)) does not seem to 
show any significant differences in normal and inflamed bladders. For this reason we 
concluded there is no change in amount of P2X1 receptors between healthy and 
cystitis urinary bladders.  
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Fig. 5.4:  Immunohistochemical labeling of bladders negative controls (e, g, i) and positive cystitis samples (f, h, 
j). All sections are counterstained with hematoxyline. Right column (f, h, j) shows the staining for P2X1 receptors. 
Pictures e, f show the urothelium and suburothelium, g,h muscle, i, j urothelium and sub-urothelium. 
 
5.2 Contraction experiments 
5.2.1 Stimulation by agonist 
 
The adenosine in concentration of 5x10
-5
 M was used as an agonist. Five types 
of antagonists were added. Propranolol and phentolamine to block unspecific 
 61 
andrenergic responses, 4- DAMP as a blocker of muscarinic receptors, PPADS 
which blocks the P2 receptors generally and DPCPX- a specific irreversible 
antagonist of P1A1 receptors. 
 
The healthy rats 
 
The relaxation of the bladder detrusor was observed and measured within one 
minute after the agonist was added. These graphs show the average values of five 
strips of the detrusor. Results for each of the graphs were obtained at the same day so 
the conditions for the measuring would be as similar as possible and the errors would 
be minimised.  
 
 
 
Graph 5.1: Healthy rats, stimulation by agonist. After agonist added, we obtained five values ( five 
strips). Each of these values was divided by maximal response to high potassium krebs. Then the average 
was noted to the graph. There is a significant difference between the states before and after DPCPX was 
added. Vertical bars represent standard error deviation.  
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Graph 5.2: Healthy rats, stimulation by agonist. For this type of graph the same values like for the previous one 
were used. The procedure of getting the numbers for this graph was very similar to the graph 1. The difference 
makes the last step, when after dividing the values by response to high potassium krebs, the average value is 
divided by response of tissue to no antagonist. Using this way we get percentage expression of results. Vertical 
bars represent standard error deviation.  
 
 
 
The cystitis rats 
 
The exactly same experiments were performed with the cystitis rats. Results 
were processed in the same way. In comparison with the normal rats, adenosine 
evoked a larger relaxatory response in the presence of 4-DAMP and the relaxation 
was to a lesser degree inhibited by the specific irreversible antagonist of P1A1 
receptors DPCPX. 
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Graph 5.3: Cystitis rats, stimulation by agonist. Again there is a significant difference in response of the 
tissue when DPCPX added. A significant differences in responses were noted after adding 4- DAMP and 
DPCPX.  Vertical bars represent standard error deviation.  
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Graph 5.4: Cystitis rats, stimulation by agonist. This graph expresses the experiment in percentages. 
Vertical bars represent standard error deviation.  
 
 
5.2.2 Electric field stimulation (EFS) 
 
Electric field stimulation is another possible way to stimulate a tissue. The 
electric field stimulation at a frequency of 40 Hz was used in the experiments. For 
about 20 seconds the detrusor strips were exposed to an EFS and the maximum 
response was used for the calculation of the responses. All ion channels are open 
during EFS, which means both systems, i.e., the one for relaxation and also the one 
for contraction, are activated at the same time. The measured value is then a sum of 
maximums and minimums, i.e., a composite response is actually recorded. 
The experiment with EFS was run with small differences compared to the 
agonist stimulation. The main difference is the order of the added antagonists. First 
of all the 4-DAMP was added to show what happens when muscarinic receptors are 
blocked. Then phentolamine and propranolol blocked the adrenergic responses. After 
washing these three antagonists away, just DPCPX, which should block just P1A1 
receptors was added to see how the response will be changed. Since DPCPX is an 
irreversible antagonist, it is impossible to wash it out, and that is why the experiment 
continued by adding all of the other antagonist. 
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Healthy and cystitis rats 
The graph shows the results in the EFS experiments and also the differences in 
the results between agonist and electric field stimulation. The same procedure was 
done with the bladder strips of cystitis rat. In the normal rats, muscarinic blockade 
reduced the contraction by 35% and the adrenergic blockade by a further 40%. In the 
presence of these antagonists DPCPX increased the response. Thus, it antagonized a 
adenosine relaxatory effect. In cystitis, this effect was close to absent. 
 
 
Graph 5.5: Healthy rats, electric field stimulation. Noted average of values divided by maximal response 
to high potassium krebs. Contrary to agonist stimulation, the EFS one show us more significant 
differences in response according to added antagonist. It is significant when 4- DAMP is added, 
significant chamge in response is also after DPCPX (according to ―no antagonist‖ column), following 
PPADS adding affects the response very obviously, in the end phentolamine and propranolol change the 
response remarkably. Vertical bars represent standard error deviation.  
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Graph 5.6: Healthy rats, electric field stimulation. This graph expresses the experiment in percentages. 
Vertical bars represent standard error deviation.  
 
 
Cystitis rats 
 
Graph 5.7: Cystitis rats, electric field stimulation. In this case we can observe a significant difference 
after adding 4- DAMP, propranolol and phentolamine kept the significant change. When washed just 
DPCPX was added and also this antagonist showed significant effect. PPADS, 4- DAMP and 
phentolamine and propranolol added in a row then lowered the response even more. Vertical bars 
represent standard error deviation.  
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Graph 5.8: Cystitis rats, electric field stimulation. This graph express the experiment in percentages. 
Vertical bars represent standard error deviation.  
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6 Discussion 
 
There are five subtypes of muscarinic receptor present in urinary bladder 
and the importance of muscarinic M3 receptors for the micturition is very well 
known (Lecci, 2002). The functional significance of all the five subtypes has not 
been established yet. But it has been proved that the subtypes of muscarinic 
receptors interact on neuronal as well as on non- neuronal cells in regulation of 
autonomic responses (Tobin et al., 2009). Lately it has been suggested that the 
muscarinic receptors subtypes are connected also with inflammation and 
proliferation (Ventura et al., 2002). 
The contraction of the urinary bladder is primarily dependent on the 
activation of muscarinic receptors. It has been showed that muscarinic M3 
receptors are mainly responsible for the bladder contraction, more than any other 
of the subtypes, even though M2 receptors may have contractile effects also. 
However, the M2 receptors contributes most significantly by facilitating 
contractions by opposing relaxations induced by adenylate cyclase- coupled 
receptors such as the - adrenoceptors and P1 purinoceptors (Hedge et al., 
1997).  
It has been suggested that exogenous ATP and adenosine relax the smooth 
muscle of the pig urethra (Werkström, 2005). The highest levels of A2B receptors 
are present in cecum, colon and bladder, followed by blood vessels, lung, eye 
and mast cells (Volpini, 2003). The immune system cells also express P1 
receptors, and the cells are then responsive to the modulatory effects of 
adenosine in an inflammatory environment. In animal models, the adenosine 
receptors have been shown to be involved in inflammatory processes such as 
asthma, arthritis, sepsis and inflammatory bowel (Haskó, 2008). 
According to already published experimental results, this project was 
focused on P1A1 receptors. The aim of this project was to give the answer to 
three questions: Exist these receptors in the urinary bladder, and if they do, 
where are they located and do their location and expression change during the 
inflammatory process of the urinary bladder. The functional studies were run to 
find out how the change of the number of receptors would change the bladder 
function. 
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Immunohistochemistry results indicated clearly that P1A1 receptors exist 
in the urinary bladder of the male rat. Very specific staining of a brown colour 
showed us that P1A1 receptors are localized in all parts of the urinary bladder- in 
urothelium, suburothelium and even in the muscle. 
The change of amount of the receptors during an inflammatory process 
was another question that I addressed. Immunohistochemistry run on the 
samples of the urinary bladder of rats pre- treated with cyclophosphamide, 
showed a different pattern compared to that in the healthy rats. The specific 
brown staining of the cystitis rat bladder was much less intensive than the 
glasses with healthy bladder. These findings support the suggestion that during 
the inflammation of the rat urinary bladder the expression of P1A1 receptors is 
decreased. 
As a control the same immunohistochemistry experiment was run with the 
P2X1 receptors. The specific staining for P2X1 receptors was used and showed, 
as been shown previously, that the receptors occur in the bladder, and that the 
intensity of the brown colour does not change significantly in inflammation. 
Tentatively, there is no change in expression of P2X1 in the cystitis urinary 
bladder of rat. 
The difference between staining for P1A1 and P2X1 receptors is 
considerable, which indicates that the immunohistochemistry results for P1A1 
are true reflections the an objective situation. This is of course strongly 
supported by the functional findings as well. 
To find out how does this change affect the bladder function, the set of 
functional experiments was run. The functional studies were based on relaxation 
and contraction experiments respectively. In the first part of the functional 
experiment adenosine was used in concentration 5x10
-5
 mol/l as an agonist for 
P1A1. To discover the best concentration of the agonist, we designed adenosine 
contraction curve. The adenosine concentration of 5x10
-5
 mol/l gave us a 
significant, sharp and relatively fast relaxation, and that was why this 
concentration was chosen for the next experiments. 
By adding adenosine we only affected postsynaptic P1A1 receptors. This 
means that the relaxation of tissue caused by adenosine is just due to receptors 
localized postsynaptically. As a selective P1A1 antagonist we used DPCPX, 
which has been used for this purpose in many other experiments.  
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To blockade as many unspecific influences as possible, the group of 
specific antagonists for all receptors defined in urinary bladder of rat were used. 
Phentolamine and propranolol for blocking any unspecific reactions of 
adrenergic receptors, 4- DAMP for inactivation of muscarinic receptors and 
nonselective purinergic receptor PPADS to blocking all P2 receptors 
(Gulbransen, 2009). 
At the beginning of each experiment the relaxation caused by the pure 
agonist was measured. Then the antagonists were added to the baths 
consecutively, and the relaxation caused by adenosine was measured every time 
after a new antagonist was added. According to these gained values, the graph 
was compiled. This experimental protocol was run twice, with healthy rat 
urinary bladders and with cystitis rat urinary bladders respectively. At the end of 
each experiment the bladder strips were weighed.  
Several different ways to approach the questions raised in the thesis work 
were applied. First we tried to divide the individual responses of the strip in mN 
by its individual weight. But this option showed to be very inexact, since size 
and weight of the strips seem to have little correlation with the strength of 
contraction or relaxation of the strip. Mostly because the strips are prepared 
manually, which gives a variation of the preparations. More accurate 
information about the strip potency was obtained when the responses in mN wre 
normalized by maximal response of the strip to the high potassium krebs. These 
results are showed in graphs with odd numbers (Graph 5.1, 5.3, 5.5 and 5.7). 
Also a very clear impression was received when we divided these numbers by 
the response in the absence of antagonist. Then the data are of course given in 
percentage, as are shown in graphs with even number (Graph 5.2, 5.4, 5.6 and 
5.8). 
In healthy rat urinary bladders no significant change of the response to 
adenosine occurred when all the non-specific antagonists were added. The only 
significant difference in the responses occurred when DPCPX (selective 
antagonist of P1A1 receptors) was added. This change shows how big the 
importance of P1A1 receptors is for the relaxation of the urinary bladder tissue. 
The relaxation was reduced by over 80% by DPCPX . Therefore I conclude that 
P1A1 receptors play a fundamental role in urinary bladder relaxation. 
 71 
A significant reduction of the relaxation of the urinary bladder strips was 
recorded also in inflammatory urinary bladder. In this case the reduction  caused 
by DPCPX amounted to 40% (reduction from 100% to 60% of relaxation). This 
change in the amount of the reduction could be caused by decreased quantity of 
the P1A1 receptors, which would support the immunohistochemistry suggestion. 
 
Electric field stimulation showed a different pattern. EFS opens all ion 
channels and EFS affect both presynaptic and postsynaptic receptors, since the 
intratissual neurons are activated also. Consequently, significant reductions in 
contraction occurred in the presence of 4- DAMP (muscarinic receptor blocker) 
and phentolamine and propranolol (adrenergic receptor blocker). However, after 
adding DPCPX the contractions to EFS once again almost reached the originally 
values before adding any blocker. That means that there has been a relaxation 
occurring that is counteracted by DPCPX. In the cystitis rats, this increase was 
absent. Also when the second round of administration of the antagonists, a 
similar pattern emerges. It is clear, there is remarkable difference between 
healthy and cystitis urinary bladder. There are few suggestions why this is 
happening which will be the objectives of next experiments. It is possible that 
cystitis would affect some other receptors, which are also sensitive to DPCPX. It 
is necessary run some more experiments to ensure that DPCPX is really just 
P1A1 antagonist and that the solution is clean and does not affect anything else, 
especially some kind of contractile receptors. The next step should be to find out 
if there is any influence of DPCPX on M5 receptors since we know their 
expression goes up during cystitis (Giglio, 2005). 
 
There is a remarkable difference in behaviour of the specific antagonist 
of P1A1 receptors DPCPX in urinary bladder strips stimulated by agonist of 
P1A1 receptors adenosine and urinary bladder strips stimulated by electric field.  
The difference may be caused by location of the stimulation. While adenosine 
stimulate just the postsynaptic receptors, EFS acts on both, presynaptic and 
postsynaptic sides. Also it is important to find out more about properties of 
DPCPX. To answer these new raised questions will be object of following 
laboratory work. 
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7 Conclusion 
 
The present study shows: 
 
1. Both P2X1 and P1A1 purinoreceptors are present in the rat urinary 
bladder. This suggestion was proved by a very specific staining of a brown 
colour. 
2. The staining also showed us that P1A1 receptors are localized in all 
parts of the urinary bladder- in urothelium, suburothelium and even in the 
muscle. For this experiment the Avidin-Biotin Complex (ABC) method was 
used.  
        3. The expression of P1A1 receptors during inflammatory process of the 
bladder is decreased. Purinergic response induced by adenosine (agonist of P1A1 
receptors) can be blocked by 80% (in healthy rat) or 40% percent respectively 
(in cystitis rat) by adding specific antagonist of P1A1 purinoceptors  DPCPX. 
Electric field stimulation showed differences in effect of DPCPX comparing to 
adenosine stimulation. 
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